Intranasal Delivery of Genistein-Loaded Nanoparticles as a Potential Preventive System against Neurodegenerative Disorders DOI Creative Commons
Giovanna Rassu,

Elena Piera Porcu,

Silvia Fancello

et al.

Pharmaceutics, Journal Year: 2018, Volume and Issue: 11(1), P. 8 - 8

Published: Dec. 29, 2018

Genistein has been reported to have antioxidant and neuroprotective activity. Despite encouraging in vitro vivo results, several disadvantages such as poor water solubility, rapid metabolism, low oral bioavailability limit the clinical application of genistein. The aim this study was design characterize genistein-loaded chitosan nanoparticles for intranasal drug delivery, prepared by ionic gelation technique using sodium hexametaphosphate. Nanoparticles were characterized their cytotoxicity tested on PC12 cells. Genistein-loaded prepared, hexametaphosphate used a valid alternative well-known cross-linkers. Nanoparticle characteristics well physical stability affected formulation composition manufacturing. Small (mean diameters 200–300 nm) homogeneous obtained able improve genistein penetration through nasal mucosa compared pure dispersions showed pH consistent with fluid preserved cell vitality.

Language: Английский

Tailoring Formulations for Intranasal Nose-to-Brain Delivery: A Review on Architecture, Physico-Chemical Characteristics and Mucociliary Clearance of the Nasal Olfactory Mucosa DOI Creative Commons

Stella Gänger,

Katharina Schindowski

Pharmaceutics, Journal Year: 2018, Volume and Issue: 10(3), P. 116 - 116

Published: Aug. 3, 2018

The blood-brain barrier and the blood-cerebrospinal fluid are major obstacles in central nervous system (CNS) drug delivery, since they block most molecules from entering brain. Alternative delivery routes like intraparenchymal or intrathecal invasive methods with a remaining risk of infections. In contrast, nose-to-brain is minimally administration pathway, which bypasses as directed nasal cavity to particular, skull base located at roof close vicinity CNS. This area covered olfactory mucosa. To design tailor suitable formulations for architecture, structure physico-chemical characteristics mucosa important criteria. Hence, here we review state-of-the-art knowledge about and, needed rational intranasal dosage forms. Also, information development systemic local well vaccinations.

Language: Английский

Citations

338
Interpreting non-linear drug diffusion data: Utilizing Korsmeyer-Peppas model to study drug release from liposomes DOI
Iren Yeeling Wu,

Sonali Bala,

Nataša Škalko‐Basnet

et al.

European Journal of Pharmaceutical Sciences, Journal Year: 2019, Volume and Issue: 138, P. 105026 - 105026

Published: July 31, 2019

Language: Английский

Citations

272
Drug delivery to the central nervous system DOI
Elizabeth Nance, Suzie H. Pun, Rajiv Saigal

et al.

Nature Reviews Materials, Journal Year: 2021, Volume and Issue: 7(4), P. 314 - 331

Published: Dec. 3, 2021

Language: Английский

Citations

220
Nanoemulsions for “Nose-to-Brain” Drug Delivery DOI Creative Commons
Maria Cristina Bonferoni, Silvia Rossi, Giuseppina Sandri

et al.

Pharmaceutics, Journal Year: 2019, Volume and Issue: 11(2), P. 84 - 84

Published: Feb. 17, 2019

The blood–brain barrier (BBB) plays a fundamental role in protecting the brain from toxic substances and therefore also controls restricts entry of therapeutic agents. nasal administration drugs using nose-to-brain pathway allows direct drug targeting into brain, avoiding first-pass effect bypassing BBB. Through route, can access directly along trigeminal olfactory nerves, which are located upper part cavity. Nanoemulsions formulations belonging to field nanomedicine. They consist emulsions (commonly oil water) stabilized by one or more surfactants—and eventually co-surfactants—delivered droplets small dimensions (sizes 100–300 nm less) with high surface area. A mucoadhesive polymer such as chitosan be added formulation impair rapid clearance. represent promising deliver through intranasal route. Therefore, they used possible alternative oral administration, problems low solubility water, poor bioavailability, enzymatic degradation slow onset action. This review focuses present situation literature regarding use nanoemulsions for targeting, particular attention recent publications. Nasal appear effective, non-invasive safe delivery systems achieve treatment neurological diseases.

Language: Английский

Citations

209
Intranasal delivery of nanostructured lipid carriers, solid lipid nanoparticles and nanoemulsions: A current overview of in vivo studies DOI Creative Commons
Cláudia Pina Costa, João Nuno Moreira, José Manuel Sousa Lobo

et al.

Acta Pharmaceutica Sinica B, Journal Year: 2021, Volume and Issue: 11(4), P. 925 - 940

Published: March 14, 2021

The management of the central nervous system (CNS) disorders is challenging, due to need drugs cross blood‒brain barrier (BBB) and reach brain. Among various strategies that have been studied circumvent this challenge, use intranasal route transport from nose directly brain has showing promising results. In addition, encapsulation in lipid-based nanocarriers, such as solid lipid nanoparticles (SLNs), nanostructured carriers (NLCs) or nanoemulsions (NEs), can improve nose-to-brain by increasing bioavailability site-specific delivery. This review provides state-of-the-art

Language: Английский

Citations

203
Key for crossing the BBB with nanoparticles: the rational design DOI Creative Commons
Sonia M. Lombardo, Marc Schneider,

Akif Emre Türeli

et al.

Beilstein Journal of Nanotechnology, Journal Year: 2020, Volume and Issue: 11, P. 866 - 883

Published: June 4, 2020

Central nervous system diseases are a heavy burden on society and health care systems. Hence, the delivery of drugs to brain has gained more interest. The is protected by blood–brain barrier (BBB), selective formed endothelial cells cerebral microvessels, which at same time acts as bottleneck for drug preventing vast majority reach brain. To overcome this obstacle, can be loaded inside nanoparticles that carry through BBB. However, not all particles able cross BBB multitude factors needs taken into account when developing carrier purpose. Depending chosen pathway BBB, nanoparticle material, size surface properties such functionalization charge should tailored fit specific route crossing.

Language: Английский

Citations

188
Solid Lipid Nanoparticles (SLNs): An Advanced Drug Delivery System Targeting Brain through BBB DOI Creative Commons
Mantosh Kumar Satapathy, Ting‐Lin Yen, Jing‐Shiun Jan

et al.

Pharmaceutics, Journal Year: 2021, Volume and Issue: 13(8), P. 1183 - 1183

Published: July 31, 2021

The blood–brain barrier (BBB) plays a vital role in the protection and maintenance of homeostasis brain. In this way, it is an interesting target as interface for various types drug delivery, specifically context treatment several neuropathological conditions where therapeutic agents cannot cross BBB. Drug toxicity on-target specificity are among some limitations associated with current neurotherapeutics. recent years, advances nanodrug delivery have enabled carrier system containing active to signaling pathways pathophysiology that closely linked central nervous (CNS) disorders such Alzheimer’s disease (AD), Parkinson’s (PD), Huntington’s (HD), multiple sclerosis (MS), brain tumor, epilepsy, ischemic stroke, neurodegeneration. At present, nano formulations, solid lipid nanoparticles (SLNs) emerged putative can deliver therapeutics (drug-loaded SLNs) across BBB at site brain, offering novel approach controlled longer circulation time, specificity, higher efficacy, more importantly, reducing biomimetic way. This paper highlights synthesis application SLNs nontoxic formulation strategy carry CNS drugs improve use treating major neurological future clinics.

Language: Английский

Citations

183
Nose-to-brain delivery of lipid-based nanosystems for epileptic seizures and anxiety crisis DOI
Cláudia Pina Costa, João Nuno Moreira, Maria Helena Amaral

et al.

Journal of Controlled Release, Journal Year: 2019, Volume and Issue: 295, P. 187 - 200

Published: Jan. 2, 2019

Language: Английский

Citations

172
On a highway to the brain: A review on nose-to-brain drug delivery using nanoparticles DOI
María Lina Formica, Daniel Andrés Real, Matías L. Picchio

et al.

Applied Materials Today, Journal Year: 2022, Volume and Issue: 29, P. 101631 - 101631

Published: Sept. 5, 2022

Language: Английский

Citations

169
Nanotherapeutics for Nose-to-Brain Drug Delivery: An Approach to Bypass the Blood Brain Barrier DOI Creative Commons
David Lee, Tamara Minko

Pharmaceutics, Journal Year: 2021, Volume and Issue: 13(12), P. 2049 - 2049

Published: Nov. 30, 2021

Treatment of neurodegenerative diseases or other central nervous system (CNS) disorders has always been a significant challenge. The nature the blood-brain barrier (BBB) limits penetration therapeutic molecules to brain after oral parenteral administration, which, in combination with hepatic metabolism and drug elimination inactivation during its journey systemic circulation, decreases efficacy treatment, requires high doses often induces adverse side effects. Nose-to-brain delivery allows direct transport by bypassing BBB increases concentration brain. present review describes mechanisms nose-to-brain discusses recent advances this area especial emphasis on nanotechnology-based approaches.

Language: Английский

Citations

136